Literature DB >> 12218224

Cytokine pattern in blister fluid and sera of patients with pemphigus.

Adone Baroni1, Brunella Perfetto, Eleonora Ruocco, Rita Greco, Daniela Criscuolo, Vincenzo Ruocco.   

Abstract

BACKGROUND: Pemphigus is a chronic auto-immune blistering disease with four main variants, i.e. pemphigus vulgaris (PV), foliaceus (PF), erythematosus (PE) and vegetans. The common histological feature of this disease is acantholysis.
OBJECTIVE: The aim of this study was to compare levels of some cytokines in blister fluid and sera of patients with pemphigus, using as control blister fluid of patients with bullous pemphigoid (BP) and bullous contact dermatitis (BCD).
METHODS: Using an immuno-enzymatic assay (ELISA), we tested 16 sera and 6 blister fluids of patients with various forms of pemphigus (13 with PV, 1 with PF, 2 with PE), the sera of 16 healthy control subjects, 5 blister fluids of patients with BP and 5 blister fluids of patients with BCD, for the presence of some cytokines (IL-10, IL-8 and IFN-gamma). Intercellular antibodies were searched for and titred; desmoglein 1 and 3 antibody levels were independently evaluated to compare them with the severity of both cutaneous and oral involvement.
RESULTS: The levels of IL-10 in the sera of patients with pemphigus were below the detection limits. IL-8 was significantly increased only in 4 samples of sera from pemphigus patients compared with controls, while IFN-gamma was detected at low levels in almost all patients compared with sera of controls. The cytokine levels in blister fluid of patients with pemphigus were significantly higher than in the sera. There was a difference between the expression of cytokines in blister fluid of control patients with BP and BCD compared with those of pemphigus patients.
CONCLUSION: This report discusses the anti-inflammatory role played by IL-10 in the chronic form of pemphigus and the hypothesis of a possible role of IL-8 in neutrophil and lymphocyte-monocyte recruitment. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218224     DOI: 10.1159/000063895

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  8 in total

1.  Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus.

Authors:  Rosangela Soares Chriguer; Ana Maria Roselino; Margaret de Castro
Journal:  J Clin Immunol       Date:  2012-03-10       Impact factor: 8.317

Review 2.  The dual nature of interleukin-10 in pemphigus vulgaris.

Authors:  Michael Jeffrey Cho; Christoph T Ellebrecht; Aimee S Payne
Journal:  Cytokine       Date:  2014-11-22       Impact factor: 3.861

3.  Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology.

Authors:  Steve Marchenko; Alexander I Chernyavsky; Juan Arredondo; Vivian Gindi; Sergei A Grando
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

4.  Blister fluid immunofluorescence in a case of pemphigus vulgaris.

Authors:  C Shanmugasekar; V R Ram Ganesh; Alamelu Jayaraman; C R Srinivas
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

5.  A hypothesis concerning a potential involvement of ceramide in apoptosis and acantholysis induced by pemphigus autoantibodies.

Authors:  Wendy B Bollag
Journal:  Dermatol Res Pract       Date:  2010-05-18

6.  Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris.

Authors:  Rodolfo Pessato Timoteo; Marcos Vinicius da Silva; Camila Botelho Miguel; Djalma Alexandre Alves Silva; Jonatas Da Silva Catarino; Virmondes Rodrigues Junior; Helioswilton Sales-Campos; Carlo Jose Freire Oliveira
Journal:  Mediators Inflamm       Date:  2017-02-22       Impact factor: 4.711

7.  Analysis of Serum Cytokine Profile in Pemphigus.

Authors:  Sang Hee Lee; Won Jin Hong; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2017-06-21       Impact factor: 1.444

8.  ST18 Enhances PV-IgG-Induced Loss of Keratinocyte Cohesion in Parallel to Increased ERK Activation.

Authors:  Mariya Y Radeva; Elias Walter; Ramona Alexandra Stach; Amir S Yazdi; Nicolas Schlegel; Ofer Sarig; Eli Sprecher; Jens Waschke
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.